Madrigal Pharmaceuticals, Inc. (MDGL) stock
Close on Nov 11, 2026Market cap $10.00BP/E –Yield –
Madrigal Pharmaceuticals, Inc. grew revenue 149.0% to $1.28B over the twelve months to Jun 30, 2026. Free cash flow was -$206.29M. At the latest close the market valued the company at $10.00B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $10.00B
- P/E ratio
- –
- Price to sales
- 7.79
- Price to book
- 19.10
- Dividend yield
- –
- Free cash flow yield
- -2.06%
Fundamentals
- Revenue
- $1.28B
- Net income
- -$325.10M
- EPS, diluted
- -$11.28
- Free cash flow
- -$206.29M
- Book value per share
- $17.97
- Diluted shares
- 29M
Trading
- Next earnings
- Feb 18, 2027 (estimated, before the open)
- Previous close
- $432.60
- Open
- $433.56
- Day's range
- $431.55 – $440.21
- Volume
- 296,900
- Average volume (20 days)
- 572,645
- Index membership
- Russell 1000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 0.73
- 52-week range
- $353.54 – $615.00
- RSI (14 days)
- 44.4
- Volatility (1 year)
- 43.6%
- Relative volume
- 0.83×
- WACC
- 8.5%
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MDGL | S&P 500 | Difference | MDGL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.2% | -2.4% | −5.8 pts | ||
| 3 months | -19.1% | -1.2% | −18.0 pts | ||
| Year to date | -25.6% | +12.3% | −37.9 pts | ||
| 1 year | -20.0% | +12.4% | −32.5 pts | ||
| 3 years | +211.9% | +78.8% | +133.1 pts | +46.1% | +21.4% |
| 5 years | +371.2% | +75.2% | +296.0 pts | +36.3% | +11.9% |
| 10 years | +2583.0% | +311.1% | +2271.9 pts | +39.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Madrigal Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate UpdatesResults
- Update
- Results
- Results
- Results
- Results
About Madrigal Pharmaceuticals
Pharmaceutical Preparations
The company is a biopharmaceutical enterprise dedicated to developing and commercializing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), an inflammatory liver condition that causes progressive scarring and organ impairment. Its principal commercial offering is Rezdiffra (resmetirom), an oral thyroid hormone receptor beta agonist taken once daily to address liver fat accumulation and fibrosis. In addition, the firm advances a clinical pipeline that includes glucagon-like peptide-1 receptor agonists, diacylglycerol O-acyltransferase 2 inhibitors, and small interfering RNA programs designed to address complementary metabolic and genetic pathways of liver disease. Its treatments target adult patients diagnosed with noncirrhotic MASH who exhibit moderate to advanced liver fibrosis.
Company profile, executives and historyMadrigal Pharmaceuticals stock: common questions
What is Madrigal Pharmaceuticals's stock price?
MDGL closed at $433.03 on Nov 11, 2026, up 0.10% on the day. Over the past 52 weeks it traded between $353.54 and $615.00.
What is Madrigal Pharmaceuticals's market cap?
Madrigal Pharmaceuticals was worth $10.00B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MDGL's P/E ratio?
Madrigal Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$11.28), so it has no meaningful P/E ratio.
How much revenue does Madrigal Pharmaceuticals make?
Madrigal Pharmaceuticals reported revenue of $1.28B for the twelve months to Jun 30, 2026, up 149.0% from a year earlier.
Does Madrigal Pharmaceuticals pay a dividend?
No. Madrigal Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Madrigal Pharmaceuticals report earnings next?
Madrigal Pharmaceuticals is expected to report Q4 FY2026 results on Feb 18, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MDGL stock performed over the past year?
Including dividends, MDGL returned -20.0% over the past year, against +12.4% for the S&P 500.
How many MDGL shares are sold short?
2M shares were sold short at the latest FINRA report, 12.71% of the float, or 7.6 days of average trading volume.
Who are Madrigal Pharmaceuticals's competitors?
Companies most similar to Madrigal Pharmaceuticals by business, industry and size include CORT, INSM, MIRM, KNSA, PTCT.
See a number that looks wrong?